Calcium is involved in the formation of bones and the reconstruction of bone tissue after fractures, maintains nerve conduction and muscle contraction, reduces the permeability of capillaries and maintains their normal osmotic pressure, and also participates in the coagulation mechanism and maintains the acid-base balance of the blood.

Calcium ion antagonists, by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells, play a role in dilating coronary arteries, reducing myocardial oxygen consumption, slowing heart rate, and lowering blood pressure. They can be used to treat variant angina, unstable angina, chronic atrial fibrillation, paroxysmal supraventricular tachycardia, etc. They also have local anesthetic effects, but are not carcinogenic or mutagenic.

Calcium ion antagonists exert their pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells; dilate the main coronary arteries and arterioles, antagonize coronary artery spasm, and increase myocardial oxygen delivery; reduce total peripheral resistance and lower myocardial oxygen consumption; prolong the effective refractory period of the atrioventricular node, slow conduction, and reduce the ventricular rate in patients with chronic atrial fibrillation and atrial flutter; reduce vascular resistance in the systemic circulation to produce a hypotensive effect; reduce afterload, inhibit myocardial contraction, and improve left ventricular diastolic function; and may have a local anesthetic effect.

This product is a broad-spectrum anthelmintic that can directly inhibit the intestinal parasites' intake of glucose, leading to the depletion of glycogen in the worms, making them unable to survive and die.